师宪平，广州医科大学教授、博士生导师。中山大学生物化学博士，美国Cedars Sinai Medical Center博士后。先后被评为广东省“特支计划”百千万工程青年拔尖人才，广州市高层次人才。担任广东省研究型医院学会医学技术转化专业委员会常务委员，广东省保健协会抗衰老产业分会常务委员，中国医药生物技术协会转化医学分会委员；国家自然科学基金项目、广东省科技厅项目、学术桥评审专家。近年来致力于肿瘤驱动基因表达调控与分子靶向治疗研究，以第一/通讯作者在Neuro-Oncology、Advanced Science、Nucleic Acids Research、Clinical Cancer Research等国际专业杂志发表论文30余篇。以项目负责人主持国家级项目5项，省市各级科研项目30余项；以主要完成人获广东省自然科学奖二等奖和教育部高等学校科学研究自然科学奖二等奖。

研究领域：

课题组长期致力于肿瘤驱动基因的表达调控与靶向治疗研究，聚焦肿瘤复发转移及对经典靶向治疗药物耐药、免疫治疗抵抗的核心难题，研究内容涵盖从转录调控（超级增强子驱动的核心转录）到蛋白翻译后修饰/降解调控的多层面系统研究，深入探究跨层面调控网络中核心驱动因子间的交互模式，揭示驱动肿瘤恶性进展的关键分子机制，并筛选具有转化潜力的分子靶标，为优化靶向治疗策略提供新思路。

部分代表性论文：

1.Enzhe Lou, Peilong Lai, Guanjie Peng, Bo Lu, Lizhen Jiang, Xinyue Li, Jinghong Chen, Ladi Mo, Qiong Mao, Haichuan Zhang, Jinxin Fang, Yi Meng, Aochu Liu, Yingyin Gao, Andong Huang, Wenhui Lin, Shiwen Hu, Zerong Guan, Xiaolan Ye, Zhenguo Liu, Liling Jiang, Yueyuan Zheng, Xianping Shi. Super-Enhancer-Driven SOX4/SMAD3 Mediate Membrane Remodeling by Regulating Phospholipid Metabolism to Accelerate Leukemia Progression. Advanced Science (Weinh). 2026 ,13(24):e12332.

2.Aochu Liu, Zhenguo Liu, Lizhen Jiang, Andong Huang, Xinqing Lin, Xinyue Li, Bingyuan Liu, Shiwen Hu, Qiang Pan, Junjun Huang, Liyuan Yin, Liling Jiang, Wei Yi, Wenjun Mao, Yueyuan Zheng, Xianping Shi. A Non-Canonical Core Transcriptional Regulatory Circuit Orchestrates Chromatin Reprogramming to Drive Osimertinib Resistance in Non-Small Cell Lung Cancer. Advanced Science (Weinh)

. 2026 ,13(46):e75765.

3.Enzhe Lou, Liling Jiang, Yueyuan Zheng, Ran Zhuo, Huan Zhou, Shiwen Hu, Chunxia Shi, Haichuan Zhang, Xinyue Li, Lizhen Jiang, Qiong Mao, Aochu Liu, Bingyuan Liu, Jinxin Fang, Jian Pan, Xianping Shi. Super-enhancer-driven TCF4 orchestrates neuroblastoma metastasis by sphingolipid-dependent membrane remodeling and ITGB1-FAK activation.Neuro Oncology. 2026. 1;28(5):1335-1351.

4.Liling Jiang, Jiamin Wang, Guanjie Peng, Haichuan Zhang, Jinxin Fang, Yingyin Gao, Enzhe Lou, Yangzhou Liu, Wa Ding, Bingyuan Liu, Qiong Mao, Lizhen Jiang, Aochu Liu, Xinyue Li, Shiwen Hu, Qiaomin Ma, Yueyuan Zheng, Zhigang Zhao, Xianping Shi. A Super-Enhancer-Driven Transcriptional Regulatory Circuit Underlying Abiraterone Resistance in Castration-Resistant Prostate Cancer. Advanced Science (Weinh). 2025,12(31):e01284.

5.Yingyin Gao, Yangzhou Liu, Xiaolan Ye , Aochu Liu , Xinyue Li, Shiwen Hu, Xin Chen, Qiaomin Ma, Ladi Mo, Liling Jiang, Lei Tan, Yongle Du, Yueyuan Zheng, Jiankun Yang, Guoxian Luo, Zhigang Zhao, Xianping Shi. Super enhancer-driven transcriptional reprogramming promotes abiraterone resistance via neuroendocrine transition and ferroptosis evasion in castration-resistant prostate cancer. Oncogene. 2026.45(36):3842-3857.

6.Wa Ding, Jinxiang Wang, Junzheng Wu, Aochu Li, Liling Jiang, Haichuan Zhang, Yi Meng, Bingyuan Liu, Guanjie Peng, Enzhe Lou, Qiong Mao, Huan Zhou, Daolin Tang, Xin Chen, Jinbao Liu, Xianping Shi. Targeting proteasomal deubiquitinases USP14 and UCHL5 with b-AP15 reduces 5-fluorouracil resistance in colorectal cancer cells. Acta Pharmacologica Sinica. 2023.44(12):2537-2548.

7.Yuening Sun, Xin Chen, Siyan Liao, Aochu Liu, Huan Zhou, Liling Jiang, Wa Ding, Wenjie Mei, Jinbao Liu, Xianping Shi. Stabilization of MYC G-quadruplex DNA by ruthenium (II) complex overcomes imatinib resistance in chronic myeloid leukemia cells harboring T315I mutation. ‌Genes & Diseases. 2022 , 7;10(2):399-402.

8.Liling Jiang, Qingyan He, Xin Chen, Aochu Liu, Wa Ding, Haichuan Zhang, Xinmei Chen, Huan Zhou, Yi Meng, Bingyuan Liu, Guanjie Peng, Chunyan Wang, Jinbao Liu, Xianping Shi. Inhibition of proteasomal deubiquitinases USP14 and UCHL5 overcomes tyrosine kinase inhibitor resistance in chronic myeloid leukaemia. Clinical and Translational Medicine. 2022,12(9):e1038.

9.Xiaoying Lan, Min Hu, Liling Jiang, Jiamin Wang, Yi Meng, Xinmei Chen, Aochu Liu, Wa Ding, Haichuan Zhang, Huan Zhou, Bingyuan Liu, Guanjie Peng, Siyan Liao , Xin Chen, Jinbao Liu, Xianping Shi. Piperlongumine overcomes imatinib resistance by inducing proteasome inhibition in chronic myelogenous leukemia cells. Journal of Ethnopharmacology. 2023, 301:115815.

10.Xianping Shi^#*, Yueyuan Zheng, Liling Jiang, Bo Zhou, Wei Yang, Liyan Li, Lingwen Ding, Moli Huang, Sigal Gery, De-Chen Lin, H Phillip Koeffler. EWS-FLI1 regulates and cooperates with core regulatory circuitry in Ewing sarcoma. Nucleic Acids Research. 2020;48(20):11434-11451.

部分代表性项目：

1.国家自然科学基金面上项目，82670241，转录-蛋白稳态偶联环路ZEB2-TRIM44激活丝氨酸代谢驱动表观重塑促进慢粒白血病急髓变的作用机制，2027.01-2030.12，49万，在研，主持

2.国家自然科学基金面上项目，82170177，核心转录调控环路促进慢性髓系白血病急髓变的作用与机制研究，2021.12-2025.12，55万，结题，主持

3.国家自然科学基金面上项目，81670154，USP14对Bcr-Abl降解的调控及其在慢粒白血病伊马替尼耐药中的作用，2017.12-2020.12，57万，结题，主持

4.国家自然科学基金面上项目，81470355，去泛素化酶抑制剂克服肿瘤硼替佐米耐药的机制研究，2014.12-2018.12，70万，结题，主持

5.国家自然基金青年项目，81100378，重构小分子化合物SNS-032靶向Bcr-Abl酪氨酸激酶对抗慢粒格列卫耐药的作用机理，2011.12-2014.12，24万，结题，主持

6.深圳市政府研究专项，B2402019，基于单细胞多组学的结直肠癌肝转移超级增强子调控机制研究，2025.01-2028.12，291万，在研，广医负责人

成果奖项

1.广东省科学技术奖自然科学奖二等奖，2024

2.高等学校科学研究自然科学奖二等奖，教育部，2021

3.中华医学科技奖三等奖，2017、2026

4.广州市科学技术进步奖一等奖，2016

招生专业：基础医学（免疫学，病理生理学）、肿瘤学、生物化学与分子生物学

电子邮箱：xianping.shi@gzhmu.edu.cn

课题组风采展示